Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects:

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects:

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects:

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects:

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects:

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects:

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects:

Mean body weight of different groups at baseline and along four weeks of experimental procedures. by Deborah Ribeiro Frazão (9188152)

Percent Decrease in FGM between Oldest (45-49 years) and Youngest (15-19 years) Cohorts of Women over the years in Egypt. by Shatha Elnakib (8901764)

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

Subjects:

Estimated infection intensity (mean egg count per gram) for infected stools. by Roland Proud (11764892)

Subjects:

Mean amplitude of the Slow Delta Envelope and period of Slow Delta oscillations in the disconnected hemisphere, compared with respect to wakefulness and NREM sleep in the reference... by Michele Angelo Colombo (22446342)

Training impact on electrical properties of P3 lumbar MNs. Rin: input resistance. Rheobase: lowest intensity of current injected in MNs to elicit an action potential (AP). AP threshold: voltage measured at the foot of the AP. AP amplitude: measured between the resting membrane potential and the AP peak. AP half width: time spent by the potential > 50% of the AP maximum amplitude. AP rise time: time spent by the potential between 10% and 90% of the AP maximum amplitude. AP half decay time: time spent by the potential between the AP maximum amplitude and the 50% decreasing amplitude. ADP: after-depolarization potential. All values are means ± SEM. The number of MNs recorded is indicated between brackets. ns: no significantly different.... by Camille Quilgars (21156495)

“…All values are means ± SEM. The number of MNs recorded is indicated between brackets. ns: no significantly different. …”

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects: